Cost-effectiveness of care for patients with type 2 diabetes, an evaluation of an innovative shared diabetes care model.
Recruiting
- Conditions
- Diabetes Mellitus type 2
- Registration Number
- NL-OMON24530
- Lead Sponsor
- Institute of Research in Extramural Medicine, VU University Medical Center, Amsterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 1200
Inclusion Criteria
1. Patients with type 2 diabetes;
2. Age 40-75 years;
3. Written informed consent;
4. Capable to fill in questionnaires;
5. Understanding of Dutch language.
Exclusion Criteria
Patients will be excluded for participation in this study if no beneficial effects can be expected in favour of the patient, according to the opinion of the GP.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. The risk of developing coronary heart disease (using the UKPDS risk engine at baseline, 2 yrs before and year 1 and 2 after baseline); <br>2. All direct and indirect costs (cost diary); 3. Costs per lifeyear gained.
- Secondary Outcome Measures
Name Time Method 1. Absolute levels of fasting glucose; <br>2. HbA1c level; <br>3. Blood pressure; <br>4. Cholesterol; <br>5. Percentages adequately controlled patients (in accordance with the NHG standards); <br>6. Diabetes specific and generic quality of life; <br>7. Patient satisfaction; <br>8. Quality of life; <br>9. Quality of care as experienced by the patient; Percentage of patients that received all 3-monthly check-ups, a complete annual check-up, were hospitalized; <br>10. Total mortality measured by life expectancy; <br>11. Total morbidity measured by morbidity-free life expectancy and the net present value (NPV) of the number of life years gained; <br>12. QALY’s gained for the intervention scenario compared to the current practice scenario; <br>13.The NPV of total intervention costs; <br>14. The NPV of total costs of care for diabetes and its complications; 15. Incremental costs per QALY gained.